Shahidehpour Ryan K, Nelson Peter T, Katsumata Yuriko, Bachstetter Adam D
Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY 40536, USA.
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA.
Brain. 2025 Jan 7;148(1):89-101. doi: 10.1093/brain/awae258.
Genetics and other data modalities indicate that microglia play a critical role in Alzheimer's disease progression, but details of the disease-driving influence of microglia are poorly understood. Microglial cells can be parsed into subtypes based on their histological appearance. One subtype of microglia, termed dystrophic microglia, is characterized structurally by fragmented processes and cytoplasmic decay, and their presence has been associated with ageing and neurodegeneration. Recent studies suggest that the interaction between tau proteins and amyloid-β might induce dystrophic changes in microglia, potentially linking amyloid-β and tau pathologies to their effects on these microglia. We developed a study of human brains to test the hypothesis that dystrophic microglia are involved in Alzheimer's disease progression. We speculated that if their presence is unique to Alzheimer's disease neuropathological change, they would be substantially more common in Alzheimer's disease neuropathological change than in neurodegenerative diseases characterized by other proteinopathies, e.g. α-synuclein or transactive response (TAR) DNA-binding protein 43 kDa (TDP-43) pathology. Our analyses used histologically stained sections from five human brain regions of 64 individuals across six disease states, from healthy controls to advanced Alzheimer's disease stages, including comparative conditions such as Lewy body disease and limbic-predominant age-related TDP-43 encephalopathy neuropathological change. Using stereological sampling and digital pathology, we assessed populations of ramified, hypertrophic and dystrophic microglia. We found a significant increase in dystrophic microglia in areas affected early by Alzheimer's disease neuropathological change, suggesting a disease-specific role in neuropathology. Mediation analysis and structural equation modelling suggest that dystrophic microglia might impact the regional spread of Alzheimer's disease neuropathological change. In the mediation model, tau was found to be the initiating factor leading to the development of dystrophic microglia, which was then associated with the spread of amyloid-β and tau. These results suggest that a loss of the protective role of microglia could contribute to the spread of Alzheimer's disease neuropathological change and indicate that further research into preserving microglial function might be warranted.
遗传学和其他数据模式表明,小胶质细胞在阿尔茨海默病进展中起关键作用,但对小胶质细胞驱动疾病的影响细节了解甚少。小胶质细胞可根据其组织学外观分为不同亚型。小胶质细胞的一种亚型,称为营养不良性小胶质细胞,其结构特征是突起碎片化和细胞质衰退,它们的存在与衰老和神经退行性变有关。最近的研究表明,tau蛋白与淀粉样β蛋白之间的相互作用可能会诱导小胶质细胞发生营养不良性变化,这可能将淀粉样β蛋白和tau病理与其对这些小胶质细胞的影响联系起来。我们开展了一项对人类大脑的研究,以检验营养不良性小胶质细胞参与阿尔茨海默病进展这一假设。我们推测,如果它们的存在是阿尔茨海默病神经病理变化所特有的,那么它们在阿尔茨海默病神经病理变化中会比在以其他蛋白病为特征的神经退行性疾病中更为常见,例如α-突触核蛋白或反应性转录(TAR)DNA结合蛋白43 kDa(TDP-43)病理。我们的分析使用了来自64名个体的五个脑区的组织学染色切片,这些个体处于六种疾病状态,从健康对照到晚期阿尔茨海默病阶段,包括诸如路易体病和边缘叶为主的年龄相关性TDP-43脑病神经病理变化等对照情况。我们使用体视学抽样和数字病理学评估了分支状、肥大性和营养不良性小胶质细胞的数量。我们发现,在早期受阿尔茨海默病神经病理变化影响的区域,营养不良性小胶质细胞显著增加,这表明其在神经病理学中具有疾病特异性作用。中介分析和结构方程模型表明,营养不良性小胶质细胞可能会影响阿尔茨海默病神经病理变化的区域扩散。在中介模型中,tau被发现是导致营养不良性小胶质细胞形成的起始因素,随后与淀粉样β蛋白和tau的扩散相关。这些结果表明,小胶质细胞保护作用的丧失可能会导致阿尔茨海默病神经病理变化的扩散,并表明可能有必要进一步研究如何保留小胶质细胞功能。